Development of Indicators to Assess Quality of Care for Prostate Cancer.

Autor: Nag N; Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia., Millar J; Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia; Radiation Oncology, Alfred Health, Melbourne, Victoria, Australia., Davis ID; Eastern Health Clinical School, Monash University, Melbourne, Victoria, Australia., Costello S; Southern Cancer Network, Southern Alliance Programme Office, Christchurch District Health Board, South Island, New Zealand., Duthie JB; Bay Urology, Tauranga, New Zealand; Tauranga Hospital, Tauranga, New Zealand., Mark S; Christchurch Hospital, Christchurch, New Zealand., Delprado W; Douglass Hanly Moir Pathology, Sydney, New South Wales, Australia., Smith D; Cancer Council New South Wales, Woolloomooloo, New South Wales, Australia., Pryor D; Australian Prostate Cancer Research Centre, Queensland University of Technology, Queensland, Australia., Galvin D; Department of Urology, St. Vincent's University and Mater Misericordiae Hospitals, Dublin, Ireland., Sullivan F; Prostate Cancer Institute, NUI Galway, Galway, Ireland., Murphy ÁC; Molecular Medicine Ireland, Dublin, Ireland., Roder D; Department of Health Sciences, University of South Australia, South Australia, Australia., Elsaleh H; Department of Radiation Oncology, Canberra Hospital and the Australian National University, Canberra, Australian Capital Territory, Australia., Currow D; Cancer Institute New South Wales, Eveleigh, New South Wales, Australia., White C; Faculty of Health, University of Tasmania, Hobart, Tasmania, Australia., Skala M; W.P. Holman Clinic, Royal Hobart Hospital, Hobart, Tasmania, Australia., Moretti KL; University of Adelaide, University of South Australia, Flinders University of South Australia, and South Australian Prostate Cancer Clinical Outcomes Collaborative, Adelaide, South Australia, Australia., Walker T; College of Health and Biomedicine, Victoria University, Melbourne, Victoria, Australia., De Ieso P; Northern Territory Radiation Oncology, Tiwi, Northern Territory, Australia., Brooks A; Department of Urology, Westmead Hospital, Sydney, New South Wales, Australia; Department of Surgery, University of Sydney, Sydney, New South Wales, Australia., Heathcote P; Department of Urology, Princess Alexandra Hospital, Brisbane, Queensland, Australia., Frydenberg M; Department of Surgery, Faculty of Medicine, Monash University, Melbourne, Victoria, Australia; Department of Urology, Monash Health, Melbourne, Victoria, Australia., Thavaseelan J; Perth Urology Clinic, Perth, Western Australia, Australia; Fiona Stanley Hospital, Murdoch, Western Australia, Australia., Evans SM; Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia. Electronic address: sue.evans@monash.edu.
Jazyk: angličtina
Zdroj: European urology focus [Eur Urol Focus] 2018 Jan; Vol. 4 (1), pp. 57-63. Date of Electronic Publication: 2016 Feb 20.
DOI: 10.1016/j.euf.2016.01.016
Abstrakt: Background: The development, monitoring, and reporting of indicator measures that describe standard of care provide the gold standard for assessing quality of care and patient outcomes. Although indicator measures have been reported, little evidence of their use in measuring and benchmarking performance is available. A standard set, defining numerator, denominator, and risk adjustments, will enable global benchmarking of quality of care.
Objective: To develop a set of indicators to enable assessment and reporting of quality of care for men with localised prostate cancer (PCa).
Design, Setting, and Participants: Candidate indicators were identified from the literature. An international panel was invited to participate in a modified Delphi process. Teleconferences were held before and after each voting round to provide instruction and to review results.
Outcome Measurements and Statistical Analysis: Panellists were asked to rate each proposed indicator on a Likert scale of 1-9 in a two-round iterative process. Calculations required to report on the endorsed indicators were evaluated and modified to reflect the data capture of the Prostate Cancer Outcomes Registry-Australia and New Zealand (PCOR-ANZ).
Results and Limitations: A total of 97 candidate indicators were identified, of which 12 were endorsed. The set includes indicators covering pre-, intra-, and post-treatment of PCa care, within the limits of the data captured by PCOR-ANZ.
Conclusions: The 12 endorsed quality measures enable international benchmarking on the quality of care of men with localised PCa. Reporting on these indicators enhances safety and efficacy of treatment, reduces variation in care, and can improve patient outcomes.
Patient Summary: PCa has the highest incidence of all cancers in men. Early diagnosis and relatively high survival rates mean issues of quality of care and best possible health outcomes for patients are important. This paper identifies 12 important measurable quality indicators in PCa care.
(Copyright © 2016 European Association of Urology. Published by Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: